Express Pharma December 1-15, 2012 Part -2

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

59

Express Pharma Business Avenues

60

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

61

Express Pharma Business Avenues

62

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

63

Express Pharma Business Avenues

64

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

65

Express Pharma Business Avenues

“ The 1st Indian Silicone Rubber Product Mfg. co, certified with Clean Room of class 10000” SILICONE RUBBER PRODUCT G Silicone Transparent Tubing's (USP / FDA Grade) G Silicone Transparent Braided Hose (USP / FDA Grade) G FBD Inflatable Gaskets in Silicone Transparent G Rubber and also in Food Grade Neoprene Rubber

Silicone Transparent Tubing & Braided Hose Conforms to USP Class VI Requirement & FDA 21 CFR 177.2600 (AVAILABLE IN PLATINUM & PEROXIDE CURED)

Silicone & Viton Rubber O Rings

G Platinum Cured Silicone Transparent Tubes G Platinum Cured Silicone Transparent Braided Hose G Platinum Cured Silicone T/c Gaskets G Silicone Extruded Door Gaskets (Autoclavable)

FBD Inflatable Gasket Conformd to FDA 21 CFR 177.2600

Silicone Extruded Door Gasket

G Silicone Stripss, Cords &sponge Gaskets ISO 14644-1 Certified Clean Room

G Rubber Expansion Joint/Bellows G Viton O-Rings, Cords & Strips G O-Rings (Viton & Silicone) G Tri Clover Gasket G Silicone & Viton Sheets

Quality Management System

Environmental Management System Occupational Health Safety Assessment System m

Ami Polymer Pvt. Ltd. (The Sealing Expert in Silicone Rubber)An ISO : 2008 Certified Co.) 15 & 303, Mahesh Industrial Estate,Opp.Silver Park, Mira Bhayandar Rd.,Mira Road (E), Dist. Thane, Mumbai-401 104 Tel.: 91-22-28555107/ 28555631/ 28555914 Fax : 91-22-28555378 Email :amipolymer@vsnl.com Url : www. amipolymer.com BRANCHES

66

HYDERABAD

BADDI (H.P)

BANGALURU

ROORKEE

MAHARASHTRA

GOA

INDORE

09246502943/42 hybd@amipolymer.com

09218595103 / 09218595011 Baddi@amipolymer.com

09916072800/ 08691013931 bngl@amipolymer.com

09219691095/ 09219521095 roorkee@amipolymer.com

09223290933/ 09223290933 amipolymer@vsnl.com

09223290935 goa@amipolymer.com

07869267791/ 09816595011

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

67

Express Pharma Business Avenues

68

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues Advertise in

Business Avenues Please Contact: ■ Mumbai: Rajesh Bhatkal 09821313017 ■ Delhi: Ambuj Kumar 09999070900 ■ Chennai: Vijay Kulkarni 09940047667 ■ Bangalore: Khaja Ali 09741100008 ■ Hyderabad: A K Shukla 09849297724 ■ Kolkata: Ajanta / Prasenjit Basu 09831182580 / 09830130965 ■ Ahmedabad: Rajesh Bhatkal 09821313017

CLEANING, SANITISING EQUIPMENTS CLEAN ROOM ACCESSORIES ASEPTIC PIPING , PW / WFI DISTRIBUTION LOOPS

Floor Drain Traps

Hand Sanitiser

Water Saver Cleaninng Nozzles(self-rotating) Nozzles

Shoe Cover Dispenser

Foot Sanitiser

Split Butterfly Valve

Pendents(Service Shafts) CIP/ SIP MODULE We also design & manufacture # IBC Washing/ Drying Modules # Containers/ Glass Ware Wash Modules # FBD Bag Washing/ Drying Modules # Cannisters Washing Modules # Drums Washing Modules

December 1-15, 2012

Wash Down Hose Station

SIP MODULE

8/B, Surat Singh Est ,SV Rd, Jogeshwari(W), Mumbai-400102 Tel; 022-26797941 Telefax:022-26798066 Cell: 9869231815 email: iewi@mtnl.net.in website : www.iewi.net

www.expresspharmaonline.com

Top Tank / Reactor Sampler

Flush Bottom valve

EXPRESS PHARMA

69

Express Pharma Business Avenues

Type Double Door Type Double Door , Rubber Burg / Stopper Processor

metalchem@vsnl.net / metalchem@sify.com

70

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

71

Express Pharma Business Avenues

72

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

73

Express Pharma Business Avenues

74

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

75

Express Pharma Business Avenues

76

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

77

Express Pharma Business Avenues Successful Installation in Beverage Ind. upto 25Kl/hr.

More than 50 Filter Presses are in Operation

Product Range : Horizontal Plate Filter Press Plate And Frame Filter Press Bag Filter Cartridge Filter Single Plate Filter Holder Basket Filter Rotary Spray Ball Recess Plate Filter Press

Parksan Filters Pvt. Ltd. 103, Laxmi Industrial Estate, Navghar, Vasai Road (East), Dist: Thane - 401 210, India T : +91 250 239 1904 Mob : +91 98338 83114 E : sales@parksanfilters.com Web : www.parksanfilters.com

78

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

79

Express Pharma Business Avenues

80

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

81

Express Pharma Business Avenues

82

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

83

Express Pharma Business Avenues

84

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues www.airtechsys.in

An ISO 9001: 2008 Certified Company

The art of air management

the leading air management solution provider...

Airtech is a customized air solutions provider. Since its inception in 1992, Airtech has cultivated an in-depth understanding and expertise of executing turnkey HVAC & Clean Room Projects.

Airtech undertakes complete project management comprising of design, supply, installation & commissioning and validation of HVAC and Clean Room Systems.

Airtech's Clean Room system provides an ultra-clean environment ranging from Class 100 to Class 100000 with effective control of Air flow, Pressure, temperature, Relative humidity and Filteration suitable for Clean room applications.

Modular Clean Room PUF / EPS WALL / CEILING Partitions -Thickness Range: 50-200 mm.

HVAC System

Clean Room

CLEAN ROOM EQUIPMENT AND ACCESSORIES

Reverse Laminar Air Flow (Dispensing & Sampling Booth)

Horizontal LAF Unit

Air Showers

Static Pass Box

Dynamic Pass Box

Garment Cubicle

EXPERTS IN HVAC & CLEAN ROOM SOLUTIONS Airtech offers Validation services which comply with DQ, IQ, OQ & PQ protocols conforming to following WHO cGMP US FDA UK MHRA AUS TGA International Standards ( Green Field Projects ): South Africa MCC

AIRTECH

CORPORATE OFFICE: (Mumbai) B-110, Hind Saurashtra Estate, Marol Naka, Andheri (East), Mumbai - 400 059.

Tel: +91 9322218023 /+91 9324644630 /+91 9699626434 /+91 22 28592275 E-mail: sales@airtechsys.in, sunil.airtech@gmail.com • Website: www.airtechsys.in

DEALERS December 1-15, 2012

ENQUIRY www.expresspharmaonline.com

VISIT OUR STALL AT P-MEC-2012 21-23 NOV. HALL No.6 STALL No. B-64

SOLICITED EXPRESS PHARMA

85

Express Pharma Business Avenues

86

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues E-mail: alokunipal@alokind.com

Alok Industries Limited (Alok) is the largest diversified and integrated textile manufacturer in India.

Alok's state-of-the art Packaging Division, amongst the largest in the country, has purchased the licence to produce UNIPAL corrugated pallets in India under the brand name, "Alok Unipal". “Alok Unipal" is a modular system to manufacture corrugated pallets. UNIPAL currently operates in more than 10 countries across the world and is known to outperform all other corrugated pallets in the market today.

An "Alok Unipal" Corrugated pallet is a patented, innovative system with flexible construction, high strength characteristics made of water resistant Kraft paper which does not require any fumigation for Export Purposes .By choosing "Alok Unipal" you will be choosing an environmentally friendly way of doing business.

Versatile: Size from 400 mm to

Hygienic: a totally clean solution

1900 mm

Customisable: tailor-made to your

Superior: dynamic loads up to 1 MT

requirements

static loads up to 4.5 MT

Efficient: Save money by assembling on

Light weight: between 6 to 10 Kgs

location

Compliant: in line with international shipping

Flexible: 2- or 4 -way entry

requirements ISPM 15

Safe: Secure handling

Can be assembled at point of use

Recyclable: 100% No fumigation required

Contact Details Plant Address: Survey No. 87/1 & 96/1, Falandi, Umarkui Road, Silvassa -396230 (U.T. of D.N. & H.) Corporate Office: Peninsula Towers, Peninsula Corporate Park, G.K Marg Lower Parel, Mumbai-400013 M.: 898 000 3486, 834 777 0005, 9099012209 | E.: alokunipal@alokind.com | W.: www.alokind.com December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

87

Express Pharma Business Avenues

88

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

89

Express Pharma Business Avenues

90

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

Innovation is our culture…

Preclinical Toxicology Services: Single dose (Acute ) toxicity studies Repeated dose (14, 28, 90 & 180 Days) toxicity studies • Skin, Eye Irritation / corrosion • Skin Sensitization • Pharmacokinetic studies on Beagle dogs • LD50 and maximum tolerated dose • Immunotoxicity • Genotoxicity Studies • •

• • • • •

Test Systems: Mouse (Balb-C, Swiss-Albino, C57, Diabetic) Rat (Sprague Dawley, Wistar) Rabbit (New Zealand White, Non albino) Guinea Pig (Hartley) Canine (Beagle Dogs)

SERVICES Formulation Development.

Microbiological Studies.

Biological Studies.

Pre Clinical Studies.

Analytical Research.

Bio-equivalence Studies.

Clinical Trials.

Dossier Preparation.

Preclinical Pharmacopoeial Services.

Quality in our genes…

Pharmacopoeial Services: (Accredited by NABL for ISO/IEC 17025:2005)

• • • • • • • •

Pyrogen Testing Abnormal Toxicity Undue Toxicity Bioassays Systemic Injection Test Intracutaneous Test Implantation Test Eye Irritation Test

Facility Infrastructure: Individually Ventilated Cages Designed as per GLP/ AAALAC Independent facility for Rats, Mice Rabbits and Beagle Dogs • Ultra modern Histopathology lab • Safety alarms/call to scientists • Online Recording of Observations • • •

ACCREDITATIONS USFDA registered cGMP control testing laboratory.

DSIR approved R & D Centre.

Drugs Controller General of India (DCGI).

NABL accreditation for Chemical, Biological Medical Testing, Bioanalytical & Mechanical.

Recognized by Bureau of Indian Standards.

Drugs Control Administration (A.P).

Department of Biotechnology approved Institutional Bio-Safety Committee (IBSC).

NABL for ISO/IEC 17025:2005.

!"! $!%!&'('%" )*!+",+'- ,% ./012 324. !*' 5'-,&%'5 "6 '%-7*' "6"!8 ,%"'&*,"9: -'+7*,"9 !%5 ;!-"'-" *'"*,'<!8=

ONE STOP SOLUTION FOR PHARMACEUTICAL RESEARCH

SIPRA LABS LIMITED Industrial Estate, Sanathnagar, Hyderabad – 500 018.

Industrial Estate, Sanathnagar, Hyderabad – 500 018.

Tel: 040-23802000, Fax: 040-23802005 Email:sipra@sipralabs.com web: www.sipralabs.com December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

91

Express Pharma Business Avenues

92

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

93

Express Pharma Business Avenues

sales@SpectrumInstrumentsControls.com www.SpectrumInstrumentsControls.com for instant quote Call +91 9820777889

94

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

95

Express Pharma Business Avenues

96

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

97

Express Pharma Business Avenues

98

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

99

Express Pharma Business Avenues

100

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

PHOTON AUTOMATIONS PVT. LTD

SPECIALISE IN CLEANROOM DESIGNING & INSTALLATION, PUF & EPS PANELS, DOORS & DOOR INTER LOCKING SYSTEM

Our Clients: Ratio Pharm Choksi Laboratories Primium Serum Bharat Parentrals Anjanaya Biotech Vergo Pharma R&D Tech... etc.

For more information contact :

PHOTON AUTOMATIONS PVT. LTD Manufacturer, Supplier and Exporter of Cleanroom, Door & Door Inter Locking System 34, Shahaji Raje Co-op. Housing Society, Bhosale Nagar, Hadapsar, Pune - 411028, India.

Phone: +91-88050-60111 Email : photonautomations@yahoo.in / photonpune@gmail.com Web: http://www.photonautomations.com

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

101

Express Pharma Business Avenues

102

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

103

Express Pharma Business Avenues

104

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

105

Express Pharma Business Avenues

106

EXPRESS PHARMA

www.expresspharmaonline.com

December 1-15, 2012

Express Pharma Business Avenues

THE UNITED ENGINEERING COMPANY

UNITED “AFS-10” HI – SPEED AUTOMATIC AMPOULE FILLING AND SEALING MACHINE

UNITED “SAL” FULLY AUTOMATIC SELF ADHESIVE VERTICAL BOTTLE LABELING MACHINE FOR ROUND / OVAL / FLAT BOTTLE(SINGLE / BOTH SIDE LABELLING)

OUTPUT: 15000 to 18000 Ampoules/Hour RANGE : 1 ml. – 10 ml.

OUTPUT – 3000 to 12000 Bottles/Hour (Output depends on Bottle size & Label size)

Salient Features : n

n

Salient Features :

In feed of empty washed and sterilized ampoules with the help of conveyor or S.S.

n

Hopper and S.S. Tray.

n

Automatic collection of filled and sealed ampoules in erect position.

n

Vertical & Horizontal adjustment of label applicator and label position to handle

n

Both sides labelling machine is available for flat bottles.

Same machine can handle round and flat bottles with minimum change parts.

n

Individual No Ampoule No Fill Arrangement.

n

S.S. 316 L syringe with rotary valve with a single volume adjuster.

Accurate Label Placement.

Label dispensing with Servo Motor and Servo Drive for better accuracy. different size of bottles by means of Hand wheel.

n

A.C frequency drive & geared motor.

n

n

Fully PLC controlled with touch screen & HMI.

n

n

Machine body fabricated with Stainless Steel 304 quality.

n

Machine body is fabricated with S.S. 304 Structure & Cover.

n

Easy change over with minimum setting time for different size of ampoules.

n

Easy Change Over.

Fully PLC controlled touch screen with HMI & AC Frequency Drive.

“UNITED” PROUDLY INTRODUCES MOST COMPACT HI-SPEED ONLINE VIAL WASHING MACHINE WITH ULTRASONIC WASH AND PLC SYSTEM MODEL – “OL-VW-12”

UNITED HI-PRO “ ARBW” AUTOMATIC ROTARY BOTTLE WASHING MACHINE

CAPACITY - 5ml. to 30ml. Round Vials.

OUTPUT - 10000 to 14000 Round Vials/Hour

CAPACITY - 10ml. to 1000ml. Round Bottles.

OUTPUT - 4800 to 8400 Bottles /Hour.

Salient Features : n

Salient Features : n Most Compact Design.

No Bottle No Washing. n Machine supplied with 2 pumps for two different media of water fitted with filter and s. s. housing. n Conveyor driven by separate motor with AC Frequency Drive n The washing area is covered with acrylic sheet. n All pipes connected to water are as per GMP standard. n Machine can be used for air/water cleaning or even combine cleaning. n Versatile machine used for Glass/PET/HDPE bottles of different shape and size with additional change parts. n Easy change over with variable size. n Automatic loading and unloading of bottles. n After washing the bottles are directly fed to the filling machine without any hand touch. n Machine will stop automatically in case of bottle jammed at out feed. n

Most Compact Design.

n

PLC with HMI and AC Frequency Drive.

n

Minimum change parts.

n

Entire machine and contact parts with water & air are made of S.S. 316.

n

Alarms for Low Pressure of Recycled Water, DM, WFI & Compressed Air.

THE UNITED ENGINEERING COMPANY 132, Damji Shamji Industrial Estate, Mahakali Caves Road, Andheri (E), Mumbai 400 093.

Phone : +91-22-2687 6919 ● Fax : +91-22-2687 6676 ● E-mail : uec.mum2@mtnl.net.in Head Office : 35A, Hazra Road, Kolkata-700 029 (INDIA) ● Phone : +91-33-2475 9744.

Fax : +91-33-2475 7727 ● E-mail : uec@cal2.vsnl.net.in

December 1-15, 2012

www.expresspharmaonline.com

EXPRESS PHARMA

107

RESEARCH

W H AT ’ S INSIDE

EXPERTISE FOR DRUG DEVELOPMENT

Alacris Theranostics enters agreement with GSK

Roche’s Avastin misses key data point in brain cancer study PG110

To use ModCell System for early stage cancer research

CLINICAL UPDATE lacris Theranostics has entered into an agreement with GlaxoSmithKline (GSK) to apply Alacris' proprietary

A

ModCell System, developed at the Max Planck Institute for Molecular Genetics and licensed exclusively to Alacris, for drug stratification using data from early stage cancer drug discovery at GSK. GSK will provide to

Alacris pre-clinical biology data from a drug discovery project in oncology. Alacris will exploit its proprietary Systems Biology model to determine the in silico effect of the inhibitor in its 'virtual clinical trial' system.

Alacris will then suggest

which cancer cell lines as well as which cancers are more likely to respond to the inhibitor. This will be based on whole genome and transcriptome data that is integrated in the Alacris' cancer model ModCell.

EP News Bureau

Scientists get £4 million from the UK govt to make ‘designer bacteria’ To develop tools for the production of useful strains of micro-organisms RESEARCH UPDATE cientists at the University of Glasgow have received £4 million from the UK Government to develop tools for the production of useful strains of micro-organisms. The money will help researchers in the Institute of Molecular, System and Cell Biology to simplify the process of designing, building, testing and modifying biological systems like bacteria for a variety of useful purposes.

A new field of science, Synthetic Biology aims to engineer or replicate biological systems to help address major global challenges such as producing low-carbon fuel, reducing the cost of industrial raw materials and producing new pharmaceuticals.

The funding is part of a larger pot of £20m set aside by the Department for Business, Innovation and Skills and distributed through the Biotechnology and Biological Sciences Research Council to help make the UK a world leader in research and application of synthetic biology. An example of such bio-engineering is biosynthetic insulin for the treatment of diabetes, which first went on sale in 1982 and now accounts for 70 per cent of the insulin sold worldwide.

Professor Marshall Stark, who is leading the project, said, "Synthetic biology aims to apply engineering principles to the development of biological systems. Microbial cells, for example yeast or bacteria, can act as microscopic factories to make a wide variety of substances, including feedstocks for the

S

December 1-15, 2012

chemical industry, additives for the food industry, antibiotics and pharmaceuticals. Yeast, for example, is used to convert sugar into alcohol through fermentation and is how we produce beers, wines and spirits. Although each cell is tiny, we can easily grow them on a massive scale, and thus obtain large amounts of products."

In order to produce micro-organisms that perform a specific function to make the desired product, the cells have to be programmed and this is done by the introduction of DNA sequences - or genes - to an existing micro-organism.

The added genes encode instructions to make ‘machines’, called enzymes, needed for the cell ‘factory’.

Stark said, "Getting the right genes into the cells in the right order is currently very difficult. Our research programme aims to develop new, much improved ways of introducing the genes and then experimenting with the addition of extra genes, deletion of existing ones, swapping one gene for another slightly different one, changing the order in which the genes are strung together, and so on, in order to get the right substances and the maximum productivity from our microbes."

The technology being developed by the scientists at Glasgow will use a remarkable family of enzymes called recombinases which act as molecular ‘scissors and glue’ for DNA. These will allow the researchers to cut the strands at precisely defined positions and ‘paste’ a new sequence into the gap.

In another application of the technology, the team hopes to be able to ‘teach’ cells to count, and to keep a

record of the number they have counted up to in their DNA. This could be very useful; for example, for knowing the number of times a cell has divided, or the number of times it has been exposed to a chemical substance.

Stark said, "By taking a ‘designbuild-test-modify’ approach, and using modular components, we hope to create organisms that will help produce valuable chemical substances economically, in high yields and with low environmental impact, or to carry out beneficial chemical transformations such as neutralisation of pollutants in waste water."

The applications of designer microorganisms are many: from bacteria that increase the efficiency and yield of biofuels to the creation of plastics from chemicals through microbial fermentation rather than fossil fuels. Bacteria could also be used to create new antibiotics to tackle superbugs.

David Willetts, Minister for Universities and Science, said, "Synthetic biology could provide solutions to the global challenges we face and offers significant growth opportunities in a range of important sectors from health to energy. However, the commercialisation of basic science is largely untapped. This investment will help to ensure that academics and industry can realise its full potential."

The £4m for the project, which is being led by Prof Stark and his colleagues Dr Sean Colloms and Dr Susan Rosser, will also fund researchers at Aberdeen, York and Nottingham Universities.

Reuters

www.expresspharmaonline.com

PHARMA ALLY 111 PHARMA LIFE 115 EXPRESS PHARMA

109

R|E|S|E|A|R|C|H

Roche’s Avastin misses key data point in brain cancer study The drug did not reach statistical significance in overall survival wiss drugmaker Roche's cancer drug Avastin failed to make a statistically significant difference to survival rates of patients with a common form of brain cancer in a late-stage study, the company said.

The phase III AVAglio study presented at the Society for Neuro-Oncology congress in Washington showed Avastin, combined with radiation and chemotherapy, reduced the risk of cancer worsening or death, the Basel-based drug-

S

maker said.

But the drug did not reach statistical significance in over-

Lilly arthritis drug shows durability in study The drug did not reach statistical significance in overall survival pill for rheumatoid arthritis being developed by Eli Lilly and Co and Incyte Corp maintained its effectiveness in reducing painful symptoms through 24 weeks of treatment in a midstage extension study, according to data presented at a medical meeting.

A sub-study of patients taking part in the trial of the drug, baricitinib, also showed that the two highest doses tested helped to reduce joint damage, based on Magnetic Resonance Imaging (MRI) tests.

The companies in June released positive data from the 301-subject phase II study after 12 weeks of treatment in patients with mild to moderate RA who had an inadequate response to methotrexate. Data from the ongoing extension study, presented at the American College of Rheumatology meeting in Washington, measured baricitinib treatment through the 24 weeks.

Based on the data collected from its phase II programmes, Lilly said it has moved into late-stage testing of the drug.

Four phase III RA studies of baricitinib using the 2 milligram and 4 mg doses are

A

110

EXPRESS PHARMA

planned for patients who have not previously been treated with methotrexate or injectable biotech drugs and also in patients who did have prior treatment with biologics, or drugs made from living organisms or their products, the companies said.

Those studies will form the basis of the data package used to seek approval of the drug.

After 24 weeks, 73 per cent of patients who received 8 mg of the Lilly drug once daily achieved the ACR20 goal, or a 20 per cent improvement in rheumatoid arthritis symptoms. That compared with 78 per cent who hit ACR20 at 12 weeks.

For the 4 mg dose, 78 per cent of patients hit ACR 20 at 24 weeks, up from 75 per cent at week 12.

The 2 mg dose that failed to show statistical significance compared with a placebo at 12 weeks had 63 per cent of patients achieve ACR20 by week 24 of treatment, the data showed.

The study also measured ACR50 and ACR70 rates, or 50 per cent and 70 per cent improvement. All three doses showed improvement at 24 weeks from measurements

taken at 12 weeks.

“These data are important because collectively they show patients experienced improvement with baricitinib as early as week two that was sustained through week 24,” Dr Mark Genovese, CoChief of the division of immunology and rheumatology at Stanford University School of Medicine, said.

“Also of note is that the percentage of patients achieving ACR50 and ACR70 increased over time and no unexpected safety findings emerged with continued dosing," said Genovese, a member of the steering committee for the study.

Baricitinib belongs to a hot new class of oral medicines called Jak inhibitors that aim to compete with the injected rheumatoid arthritis drugs that currently dominate the market with billions in sales. Pfizer Inc last week became the first company to bring one of the new drugs to market with the US approval of tofacitinib, which will be sold under the brand name Xeljanz. Jak inhibitors block enzymes believed to be involved in the inflammatory process.

Reuters www.expresspharmaonline.com

all survival, a key data point.

Further data are expected next year, Roche said.

"The interim results for overall survival (OS), the other co-primary endpoint, did not reach statistical significance," the company said in the statement.

Earlier data from the study published in August showed Avastin significantly extended progression-free survival of people with an aggressive form of brain cancer. Avastin is Roche's thirdbiggest seller and is approved to treat several types of cancer, including breast, kidney, colorectal and ovarian cancers.

Reuters

Sanofi gets boost as EU backs diabetes and cancer drugs Lyxumia was recommended for treating type II diabetes and Zaltrap was endorsed for the treatment of advanced colorectal cancer anofi won the backing of European regulators for two new drugs against diabetes and cancer, a shot in the arm for the French company's drive to bring new products to market.

New diabetes drug Lyxumia was recommended for treating type II diabetes and Zaltrap was endorsed for the treatment of advanced colorectal cancer, the European Medicines Agency (EMA) said.

Recommendations from the EMA are normally endorsed by the European Commission within two or three months and Sanofi said it expected to hear from the Commission in the first quarter of 2013.

Lyxumia, which Sanofi licensed from Denmark's Zealand Pharma, is part of a new class of diabetes treatments called GLP-1 analogues which prompt the body to release insulin when a diabetic's blood sugar level climbs too high. It is one of several new medicines Sanofi is banking on to drive growth after patent losses on former topselling drugs.

S

Pierre Chancel, Global Head of Diabetes, Sanofi, said, “The positive opinion for Lyxumia was 'an important milestone' and would help expand the company's already strong diabetes franchise, which is dominated by the long-acting insulin Lantus.”

Sanofi plans to submit Lyxumia for approval with the US Food and Drug Administration by the end of the year.

Rival GLP-1 treatments include Novo Nordisk's Victoza, and Byetta and Bydureon, from Amylin, the US drugmaker acquired earlier this year by Bristol-Myers Squibb and AstraZeneca.

Zaltrap, developed with Regeneron Pharmaceuticals, is a so-called anti-angiogenic agent, designed to starve tumours of blood. It was approved in the US in August.

Although the drug failed to live up to its promise as a treatment for prostate cancer in late-stage tests, it has shown significant improvement in overall survival in patients with colon cancer.

Reuters December 1-15, 2012

PHARMA ALLY

W H AT ’ S INSIDE

EXPERTISE FOR DRUG DEVELOPMENT

‘India is one of the strategic focus countries and growing market’ Manish Mishra, Head – Bioscience, Merck Millipore (India) speaks with Shalini Gupta about the companies future prospects and its new launches How has the acquisition of Millipore helped strengthen Merck’s position in terms of its portfolio of services for the pharma industry?

Merck’s portfolio mainly addresses the demand for advanced excipients and purification media for the manufacture of APIs and biologics in addition to chemicals for analytical purposes. The integration of Millipore considerably expands this offering to innovative and high-end research instruments in cellular analysis, multiplexing, filtration and cell culture solutions. Following a successful integration, the Merck Millipore division earned 2011 global revenues of EUR 2.4 billion.

Which are your flagship products and which segments have registered major growth? How is the company addressing the flowcytometry space? Any upcoming trends in the same?

Our bioscience business unit addresses the needs of the pharmaceutical and biotechnology industries, as well as academia, to understand complete biological systems and identify new therapeutic targets. Key products and services include multiplex instruments and kits, flow cytometry, inhibitors and biochemicals, stem cells, antibodies and reagents, drug discovery and development services and lab filtration.

Lab filtration has been our strong suit where we command 60 per cent market share in the addressable market comprising academia, biotechnology and pharma segments. We have regained our market leader position in the Sterile Filtration Portfolio that mainly caters to the pharma segDecember 1-15, 2012

INTERVIEW

ment. We have also lined up aggressive and ambitious country wide plans for our flowcytometry product offerings. The current market trend indicates an increase in demand for bench top flow cytometry systems that are easy to set up and use.

Merck Millipore’s Amnis, is a flow cytometry platform coupled with high resolution microscopy that addresses several unmet needs in the field of cell analysis and systems biology. It complements Merck Millipore’s existing Guava product range. Today there are no comparable alternatives that enable our customers to combine flow cytometry and image analysis in one integrated solution. With the launch of this product, Merck Millipore would become the only provider of this technology.

What are the pressing needs of Indian companies that offer you opportunities for growth? Who are your major clients in India?

Drug discovery companies are always on the lookout for solutions which can accelerate time to discovery.

We offer such solutions by leveraging our target profiling services, multiplex and traditional immunoassays, and clinical lab contract services that help these companies prioritise potential

drug candidates, screen many biomarkers simultaneously, and conduct research and clinical studies.

Consequently, they are fast gaining popularity with customers from pharmaceutical R&D and CROs. Majority of our customers are in the western region, Karnataka, Andhra Pradesh and some parts of Northern India.

The company is a partner to researchers. Kindly comment.

Our bioscience business unit offers products and services that simplify the work flow for researchers in a wide variety of areas ranging from neuroscience, infectious disease, oncology, and metabolic disorders to stem cells, cell signalling, nuclear function, and chromatin biology. Our flagship products like the Guava and Amnis flow cytometry range are examples of developing tools that ease the research process. Our Immunoassays and Multiplex solutions offer the first-ever, end-to-end workflow solutions for biomarker discovery and analysis. To further strengthen our commitment in advancing life science together with our customers, Merck Millipore India instituted in September 2011 the Merck Millipore India Innovation Awards (MMIIA); a first-of-its-kind, biennial programme aimed at recognising exemplary research undertaken by scientists from governmentfunded and not-for-profit public research institutes in the field of life science, i.e. green chemistry, medicinal chemistry, chemical and bioanalytics, proteomics, genomics, drug discovery and delivery, biomanufacturing, biomarkers and synthetic biology. The selection criteria are based on the innovation impact level, scientific creativity, industrial scalabilwww.expresspharmaonline.com

ity and sustainability.

The company has been one of the pioneers of innovation in terms of its products. Tell us about some such products in the market currently or newly launched and their usability.

We have more than 40,000 products and are one of the top three R&D investors in the life science tools industry globally. Our Amicon protein concentrators proved to be game changers for the division when launched and have undergone numerous developments globally based on customer feedback. The range is our premier flagship product that finds reference in thousands of research journals.

The newly launched MUSE Cell Analyzer is a miniature table top version of our Guava flow cytometer. With a single laser, it is capable of carrying out more than 10 assays with the intuitive touch screen interface. An experiment time of less than fifteen minutes that includes approximately two minutes of running time; it leads to considerable time saving per assay.

Others include Direct Detect, a FT-IR based protein quantification system for accurate protein concentration detection quantitation; and StratM, which imitates the human skin for the cosmetic industries, skin bank and research institutes.

KV Venugopalan elected as President of IAIA PG112

Malvern Instruments’ Morphologi G3-ID PG113

How is India as a market?

What policies and measures could help the industry?

India is one of the strategic focus countries and growing market for Merck Millipore. It is encouraging to see the Indian government actively support the research community by allocating funds and infrastructure.

Having said that, importfriendly customs policies would go a long way in levelling the playing field for international competitors offering quality products, where the price advantage EXPRESS PHARMA

111

P|H|A|R|M|A| A|L|L|Y

could be passed on to the endusers.

How important is a strong field sales force and technical training?

The Bioscience field force is one of the largest in the country; supported by an expansive product portfolio and a structured distribution network in Tier-I as well as

Tier-II cities.Strong synergies between the field force and R&D teams enable us to predict market trends and meet customer expectations, hence sales force should not only be competent enough to discuss these products and services with our customers; but also identify existing gaps. This is achieved by our dedicated training team that focusses on

regularly updating the sales team.

What are some of the awaited products and future plans?

One of the much awaited launches in the coming days is Amnis platform. This effectively combines the power of high-end flow cytometry with high resolution microscopy.

Additionally, there are a number of launches coming up in the multiplexing and molecular biology kits and reagents.

We are now focusing on the development of in-house products and have made sizeable investments at our R&D facility in Bengaluru. Efforts are also on to streamline our supply chain and logistics. shalini.g@expressindia.com

VENDOR NEWS KV Venugopalan elected as President of IAIA with a MBA degree in Marketing, Venugopalan has been associated with Waters India from 1983 and has presided over the company since 1997. Under his leadership, in the past 25 years, Waters business in India grew significantly and is now one of

V Venugopalan has been unanimously elected as the President of Indian Analytical Instruments Association. He is the President of Waters India, which is a fully-owned subsidiary of Waters Corporation USA. An Electronics Engineer

K

the largest analytical organisation in Indian analytical market. IAIA, an exclusive professional body was formed in 1996 with a vision to promote, encourage and develop the growth of the Analytical Instruments Industry.

EP News Bureau

PRODUCTS Mettler-Toledo launches CO2 sensor, InPro 5000i ettler-Toledo has launched a new carbon dioxide (CO2) sensor, the InPro 5000i, specifically designed for real-time dissolved CO2 measurements in biofermentation processes.

This new sensor can help predict when maintenance will be required, increasing total yield and ensuring high quality assurance.

The InPro 5000i also complies with the European Hygienic Engineering and Design Group certification, thanks to its sterilizable

M

design and effective membrane barrier against volatile organic acids. The new sensor is an addition to the Mettler Toledo Intelligent Sensor Management range of sensors and transmitters.

InPro 5000i is a fully sterilizable and autoclavable in-line CO2 sensor. The InPro 5000i's modular design makes maintenance and spare part replacement fast and convenient. The ideal housing for the sensor is

the retractable InTrac 797 as its integrated flushing chamber allows easy sensor calibration and cleaning, even during a running fermentation.

The InPro 5000i is the latest member of Mettler Toledo's Intelligent Sensor Management (ISM) family of sensors and transmitters. ISM is a digital platform for analytical measurement solutions. ISM's predictive diagnostic tools constantly monitor the InPro

5000i's 'health' so that it can be easily determined if the sensor can be safely used for the next fermentation run.

Once the sensor reaches the end of its lifetime it can be deactivated to prevent it being used at the measurement point. ISM's electronic documentation capabilities provide full traceability of sensor calibration and maintenance for regulatory compliance. In addition, the signal between sensor and transmitter is digital and is unaffected by cable length, electri-

cal interference or moisture in the environment.

The combination of sensor design and ISM technology means the InPro 5000i is ideally suited for continuous, real-time dissolved CO2 measurement in biofermentation.

Contact details: Santare Rukaite Mettler-Toledo AG Process Analytics Urdorf, Switzerland Tel. +41 44 729 6211 E-mail: santare.rukaite@mt.com

Mettler Toledo launches Stirling Engine Configuration for ReactIR 15 ettler Toledo has launched ReactIR 15 Stirling Engine (SE) MCT model. This compact, easy-touse fourier transform infrared (FTIR) reaction monitoring system offers an effective alternative to traditional MCT detectors in situations where liquid nitrogen is too costly or unsafe for routine use.

Additionally, by eliminating alignment, gas purge and maintenance, faster, simplified set-up is achieved which can significantly reduce long-term

M

112

EXPRESS PHARMA

lab operating expenses.

Along with easier set-up and less maintenance, customers have the same functional performance from the solid-state SE MCT that they

would by using a nitrogen-cooled model.

The size, weight and design of ReactIR 15—and, with SE, the absence of nitrogen-handling concerns—enables easy transfer from hood-tohood or lab-to-lab and with a wide range of sampling technology, operators can begin experimentation immediately. Ease-of-use is further enhanced for experiments running longer than 24 hours www.expresspharmaonline.com

because no refilling of the dewar is required.

Coupled with Mettler Toledo iC IRTM software, ReactIR 15 offers immediate insight into reaction initiation, endpoint, mechanism, pathway and kinetics required for successful compound development. Users can even set an automatic shut-down the instruments user preferences to extend the reactor’s working lifetime, further protecting the lab’s capital investment.

Adding iC Kinetics pro-

vides an in-depth graphic visualisation of reaction characteristics. Based on the results, operators can make decisions regarding experiment optimisation quickly, enhancing speed-of-development in today’s competitive organic chemistry marketplace.

Contact details: Patricia Hicks Mettler-Toledo AutoChem, Inc. Tel: +1-410-910-8486 Email: patricia.hicks@mt.com December 1-15, 2012

P|H|A|R|M|A| A|L|L|Y

Malvern Instruments’ Morphologi G3-ID alvern Instruments will showcase the new Morphologi G3-ID particle characterisation system at Drug Delivery to the Lungs 23, which takes place from Dec 5-7, 2012 in Edinburgh, Scotland. The company will highlight the system’s ability to generate component-specific particle size and shape data that efficiently support the commercialisation of both new and generic Orally Inhaled and Nasal Dry Products (OINDPs). Activities at the conference will include a poster presentation that details results from a new

M

study in which the Morphologi G3-ID was used to successfully measure nasal sprays in the formulated liq-

uid state with minimal sample preparation.

The Morphologi G3-ID combines imaging technolo-

Malvern Instruments’ new Zetasizer Nano ZSP ne of the most significant applications for Malvern Instruments’ new Zetasizer Nano ZSP dynamic light scattering system is the highly sensitive measurement of the zeta potential, or electrophoretic mobility, of pro-

O

teins. The instrument delivers unique performance specifications for both size and zeta potential measurement, employing an approach to zeta potential measurement that accords with the latest

industry guidance.

Published during 2012, standard guide ASTM E2865 deals with the measurement of mobility and zeta potential in systems containing biological material such as proteins, DNA, liposomes and other similar organic materials that possess particle sizes in the nanometer scale, below 100 nm. These materials are often labile, especially when subjected to an electric field, and standard electrophoretic techniques can lead to measurement of the resulting aggregates rather than the native material.

It has been shown that much of the aggregation takes place at the electrodes. In the Zetasizer Nano ZSP, use of Malvern’s patented Diffusion Barrier Technique protects the sample by isolating it from the electrode, as recommended in the ASTM standard.

Consequently the applied voltage can be switched on

gy with Raman spectroscopy to generate size, shape and chemical identification data from a single platform. In OINDP characterization it complements Malvern’s laser diffraction instruments for rapid particle size measurement – the Mastersizer 3000 and Spraytec – and indeed other techniques such as cascade impaction, by reliably differentiating even morphologically identical particles to generate data for specific formulation components. The Morphologi G3-ID therefore presents an efficient solution for applications such as: for-

eign contaminant detection; verification of active ingredient particle size pre- and post- delivery for nasal suspensions (in line with regulatory guidance); and detailed investigation of the delivered particle size of dry powder inhaler actives.

Contact details: Soloni Gosalia Marketing ManagerMalvern Aimil Instruments Tel: 00 91 22 39183596 Fax: 00 91 22 39183562 Email: soloni.gosalia @malvernaimil.com website: www.malvern.com

ExpressPharma Appointments

for longer periods to generate more reliable measurement data. The method involves the use of a unique, disposable folded capillary cell which allows measurements to be conducted on samples as small as 20 microliters.

The measurement process is simplified by the inclusion of a protein mobility measurement type in the instrument software that controls data acquisition, guides the user through the measurement and assesses and reports on data quality.

Additional tools in the software also allow calculation of protein charge.

Contact details: Soloni Gosalia Marketing Manager Malvern Aimil Instruments Tel:00 91 22 39183596 Fax: 00 91 22 39183562 Email: soloni.gosalia @malvernaimil.com Website: www.malvern.com

BD Vystra launches Disposable Pen injector D Medical, a segment of BD (Becton, Dickinson and Company), introduced the BD Vystra Disposable Pen, which was also showcased at the 2012 Parenteral Drug Association Meeting in Las Vegas. This new self-

B

December 1-15, 2012

injection pen is designed for use with a wide range of therapies that require frequent, low-volume injections or variable dosing.

BD Vystra Disposable Pen has been optimised for ease of use, comfort and reliability through rigorous ergonomic and quality assessments to ensure an intuitive, confident user experience.

Design features of this pen injector include multi-dosing, simple dose

dialing and correction with audible clicks, and large and clear dose markings.

With BD’s 115-year heritage and extensive drug delivery experience, the company is also able to offer pharma customers full-service support with worldwide reach ranging from pre-clinical to commercialisation, along with the reassurance of strong IP protection.

Contact details: Murli Sundrani Email: Murli_Sundrani@bd.com www.expresspharmaonline.com

EXPRESS PHARMA

113

P|H|A|R|M|A| A|L|L|Y

VALUE AD Tamper evident upgrade for Track & Trace Bosch Track & Trace solutions for future market requirements

CPS1900TE

ounterfeiting is a growing threat to patients and the pharmaceutical industry alike. To reduce or even eliminate this risk, the safety of the pharma supply chain is of utmost importance. With its CPS Track & Trace solution, Bosch Packaging Technology has already contributed its share.

This technology has now been upgraded by a tamper evident module.

The European Unionâ&#x20AC;&#x2122;s Directive 2011/62/EU requires the implementation of uniquely coded, serialised

C

packs for almost all prescription drugs. At the same time, the EU demands for a second layer of security, that is tamper-proof closures.

The 'unique identifier' will be determined in delegated acts, of which the first was published in November 2011. The paper has been submitted for public consultation.

Stakeholders were asked to comment on the document until the end of April 2012.

The adoption of the finalised document is scheduled for 2014. Its aim, amongst others, is the definition of the characteristics and technical specifications of the unique identifier.

Authentication, tamper-evidence and serialisation

CPS

CPS

A multi-layer approach is obviously the safest option.

The technologies available in the market can be divided into three different categories: authentication, tamper-evidence and serialization.

Authentication is provided either by overt, covert or forensic methods. They are used to identify a product or package as an original and to rule out counterfeits. Tamper evident features clearly indicate whether a package has been previously opened or tampered with. Finally, serialisation is the method used for tracing pharma throughout the supply chain. A serial number is attributed to the package and is recorded in a database, where it can be verified at any time.

Beneficial knowledge transfer between industries

Datamatrix

114

EXPRESS PHARMA

A Track & Trace system is a mass serialisation solution that prints a unique identifying code onto each product after it has been packaged.

Tracking and tracing systems have been successfully applied in the automobile industry for many years, in particular for security-relevant parts such as brakes and steering components. At this point, Bosch Packaging Technology had a competitive advantage because the company could benefit from knowledge transfer between Boschâ&#x20AC;&#x2122;s automotive field and the packaging division.

Meanwhile, Bosch Packaging www.expresspharmaonline.com

Technology has been implementing solutions for traceability and process optimisation in the pharma industry for quite some time. These solutions can be customised to individual needs, allowing Bosch to offer a wide range of technologies from basic mark and verify systems to complex tracking and tracing for complete packaging lines.

Most flexible concept for different global requirements The CPS (Carton Printing & Verifying System) is a stand-alone solution and the most flexible serialisation system on the market. Due to its small dimensions, the CPS module can easily be incorporated into any existing or new packaging process, thereby ensuring that print quality and production speed are maintained with minimal impact on the overall production output.

With its four flexible feed and outfeed belts, the CPS system can be integrated into all upstream and downstream machines of a line. After the tracking data is printed onto the package, it is automatically verified by the camera system, which reads each printed digit (OCR/OCV).

Although CPS has been developed specifically for the fast, high-quality printing of folding cartons in the pharma industry, the Track & Trace system is suited for all current and future market requirements in the pharma, food, and cosmetic industries like the serialisation of blisters, vials, folding cartons and pallets.

In addition to printing and verifying, the modular and scalable concept allows for the development of a complete system including a central control unit based on functional features such as checkweigher, labeller and tamper evident. In order to meet the market requirements and legal standards (such as Californian ePedigree, ITS Turkey and EDPS China) for marking and serialisation of folding cartons in the pharma industry worldwide, CPS can be updated and equipped with various software systems any

time. The software is divided into line processing and line administration. The latter serves as interface between the line and all established higher level systems.

CPS with integrated tamper evident labeller Bosch has now introduced an upgraded CPS including a tamper evident labeller. A maximum of 250 cartons per minute can be printed and verified at a length of approximately 2,000 millimeters. The carton can be marked on each side both from the top and from below.

Customary transparent and tamper evident seals can be provided at both flaps of the folding carton. The labels are usually verified by use of a camera system. With the new CPS 1900TE, verification of standard clear labels can be accomplished with a sensor.

This reduces the complexity of the process and enables easier handling. In order to eliminate the customerâ&#x20AC;&#x2122;s need to purchase an additional machine, this system is available with a labeller or checkweigher, or with a combination of both.

The flexibility of the system also applies to the machines that are already installed. On the CPS module, several labelling and weighing options can be added at a later stage. Any existing type of CPS system can be upgraded with the Tamper Evident module, using a retrofit kit. To keep change-over times short, the system provides tool-free format change. Therefore the system can achieve high overall equipment effectiveness (OEE). The change positions are reproducible by digital displays at spindle adjustment and scales at linear adjustment. Format positions are saved in a Human Machine Interface (HMI) format list where they can be displayed or printed any time.

Contact details: Daniel Sanwald Bosch Packaging Technology Phone: +49 711 811 57319 Email: daniel.sanwald @bosch.com December 1-15, 2012

Novo Nordisk, Quintiles in list of ‘Best Multinational Workplace’ by Great Place to Work Institute Quintiles plans virtual celebration which supports charity, employee values AWARDS

reat Place to Work Institute has revealed the names of world’s best multinational workplaces from nearly 5,700 companies that participated in Best Workplaces competitions during late 2011 to mid-2012 in 45 countries. Of the top 25 companies, Novo Nordisk is the only pharmaceutical company this year having 22nd position while Quintiles is the only CRO/ biopharmaceutical services provider on the 2012 list which bagged the 23rd position.

Responding to the news in a press statement, Lars Christian Lassen, Senior Vice President with global responsibility for human resources in Novo Nordisk commented, "We’re hon-

G

oured to receive this recognition from Great Place to Work. As a global company with more than 33,000 employees in 75 countries, we work hard to ensure a unified and thriving culture.

Our employees are among the best in the industry and their passion and commitment is the reason our company is a world leader in diabetes care.”

Tom Pike, Chief Executive Officer, Quintiles said, “As a healthcare business services company, employee engagement is an imperative. We have found a very clear correlation between employee engagement and customer loyalty, satisfaction and quality.

This recognition is not only an honour, it is proof of our

competitive differentiation.”

Pike continued, “It’s important to understand that the work we do every day helps to improve patient health around the globe.

This commitment to a healthier world is what drives most of our employees to this industry. Our ability to live up to this promise is what motivates them to stay and help our customers succeed.”

Quintiles plans to celebrate its Best Multinational Workplace designation by honouring its commitment to patients through a virtual celebration on its Facebook page. Employees and the public are invited to participate, and children around the world will benefit as Quintiles makes a donation

to the global fund for children for each employee and guest post. This donation will be earmarked for health-based initiatives among some of the world’s neediest communities.

“The companies listed on the second-annual World’s Best Multinational Workplaces List are creating workplaces dedicated to fostering trust, pride and camaraderie amongst their employees,” said Susan Lucas-Conwell, Global CEO, Great Place to Work. “Their inclusion on this prestigious list demonstrates their commitment to continually improving the lives of their employees and setting innovative new standards for workplaces of the future.”

EP News Bureau

Dow Corning’s Pune site wins DCCIA Award for best practices in safety Was recognised under the chemicals category ow Corning’s Ranjangaon site has been recognised by the Deccan Chamber of Commerce Industries and Agriculture (DCCIA) Pune for best practices in safety.

The DCCIA Pune newly instituted the ‘DCCIA Safety Award 2012’ for recognising ‘Best Safety Practices’ this year, and Dow Corning India was recognised for this award under the Chemicals category. The awards ceremony was held on October 20, 2012 in Pune where Dow Corning received this honour.

David Longo, Manager, Dow Corning for Pune site said, “Safety is one of our seven core values at Dow Corning and our team is

D

December 1-15, 2012

www.expresspharmaonline.com

committed to an injury-free work environment. While this is an important recognition of all our employees’ efforts, we should continue our journey into safety.”

Suneel Joshi, Manager Employee Safety and Security for Pune site, Dow Corning commented, “The safety award from DCCIA is a significant acknowledgement and a strategic step forward to showcase our commitment to safety and safe practices to the external world.”

DCCIA Pune was formed with the objective to promote greater cooperation between member industries and to bring them on a common platform.

EP News Bureau EXPRESS PHARMA

115

P|H|A|R|M|A| L|I|F|E

5th Annual National IAPST Convention pulls crowds The one-day event saw interesting lectures on regulatory issues

CAMPUS BEAT

he 5th Annual National Convention of Indian Association of Pharmaceutical Scientists and Technologists (IAPST) was recently held at Manipal College of Pharmaceutical Sciences, Manipal University, Karnataka. The one-day event had interesting lectures delivered on Regulatory Issues, Good Manufacturing Practices (GMP), Recent Advances in Pharmaceutical Technology, Continuing Pharmacy Education, Cosmetic Technology and Novel Drug Delivery Systems.

Dr N Udupa, Principal, (Manipal College of Pharmaceutical Sciences) MCOPS welcomed the delegates. M Sudhakar (Phillips India), Dr MD Burande, Dr AC Banerjee, Dr Biswajit Mukherjee, Dr Madhusudan Rao, Dr Saleemulla Khan (Assistant Professor, MCOPS) and Dr Anantha Naik (Professor, MCOPS) were the resource persons who delivered lectures.

Dr MS Valiathan, Former Vice Chancellor, Manipal University, made a fervent plea to the pharmaceutical and research scientists to strive collectively for generating innovative ideas for research. He identified three areas of deficit in drug dis-

T

covery and development, namely, innovation, regulatory control and ethics. He lamented that unlike China which developed artemisinin as an effective antimalarial drug, India has not produced a novel drug in the last fifty years. His advice to the young scientists was to nurture innovative ideas for research.

Dr Himadri Sen, a former research director of Ranbaxy Laboratories said that while India is doing well in pharma industry, we are not on the frontline in drug discovery TM

VISIT US AT 64th IPC, 07-09 DECEMBER 2012, CHENNAI, STALL NO. 33 (HALL NO. A4)

and development. This lacuna must be addressed through concerted research efforts.

IAPST awards were given during the inaugural function. Burande got the Pharmaceutical Professional

of the Year Award and Rao secured the Pharmaceutical Scientist of the Year award.

Banerjee in his presidential address called for excellence in research, which would help in global competitiveness. Teachers, research scholars, postgraduate and undergraduate students put up posters to present their research findings.

A panel of experts evaluated these posters. Prizes were awarded for the best three posters. The first prize went to LS Vijapur and S A Sreenivas for their poster on “Thiolated Chitosan- a vehicle for mucoadhesive drug delivery system”. The poster titled, “A survey conducted through social media sites and outcomes analysis producing various strategic results to quit smoking”,

authored by Rishab Chug, Janki Chauhan, A Priyendu and Anantha Naik Nagappa secured the second prize.

“Chitosan- curcumin complex soft tissue scaffold for tissue engineering application” bagged the third prize.

Muthukumar, N Udupa and SS Mutalik were the authors for this poster. A consolation prize was given to the poster – Image analysis as a tool for photosynthetic categorisation of related orchids.

Meenakshi Vanathi, C S Sreedhara, J Venkata Rao and N Udupa were the authors for this poster.

Dr Manthan Janodia conducted the inaugural function as the MC. Dr J Venkata Rao proposed a vote of thanks. Dr N Udupa was in charge of the valedictory function.

EP News Bureau

Subhanu Saxena to be next Cipla CEO APPOINTMENT

116

EXPRESS PHARMA

ipla, one of India’s leading pharmaceutical companies, announced that Subhanu Saxena, will come on board as Chief Executive Officer from February 1 next year. Saxena joins the $ 1.4 billion Cipla, founded in 1935, and a considered a thorn-in-the-side of big pharma, with products like its revolutionary cocktail of anti-retroviral medications priced at less than a dollar a day, at a time when the Indian major is consolidating its presence in key geographies.

The company has made a bid for a controlling 51 per cent stake in its marketing arm in South Africa, Cipla Medpro.

Saxena comes to Cipla with rich work experience of 25+ years, having worked most recently with Novartis Pharma as well as with com-

C

panies such as Citicorp, The Boston Consulting Group, and PepsiCo, across markets in Europe, North America, Africa and Asia.

In his last assignment he led the Global Product Strategy and Commercialisation functions at Novartis Pharma AG. In this role, Saxena was a part of the Global Pharma Executive Committee ($30 billion sales), with responsibility for marketing, sales, global medical affairs and health economics.

He has a graduate degree in Engineering from Oxford University and an MBA from INSEAD, France.

The Board sub-committee entrusted with the search process was particularly impressed with Saxena’s work experience in diverse industries—non-pharma as well as www.expresspharmaonline.com

pharma--in diverse geographies, in successfully managing large and complex profit businesses, and the culture fit with Cipla and its core values.

In an immediately preceding assignment, Saxena, as CEO and Country President of Novartis Pharma UK, led a business turnaround resulting in the company’s pharma organisation becoming one of the fastest growing UK pharma businesses.

In the last one year, Cipla has staffed senior executives in some of its key business functions, verticals and geographies, including key corporate and business heads in markets such as Europe and Australia, and corporate functions such as HR, IT, Legal and Strategy. Saxena will report to the Chairman and the Board of Directors of the

company.

Speaking of the appointment, Dr Yusuf K Hamied, Chairman, Cipla said, “We are delighted to have found such a good match for Cipla in Saxena. Cipla has a strong vision for the future. I am confident Saxena will build on Cipla’s core values to deliver the next phase of growth, competitiveness and return on shareholder value.”

Saxena said, “It is indeed an honour and privilege to be working for Cipla. I am looking forward to working with such a talented and committed team, under the guidance of Dr Hamied and the Board.

Cipla has achieved several milestones but a wider canvas lies ahead in terms of opportunity and areas for growth”.

EP News Bureau December 1-15, 2012

World class portfolio of products and technology www.thermoscientific.com

www.thermoscientific.com/dionex

Gas Chromatography

LIMS and Laboratory Software

Liquid Chromatography

Elemental Analysis

Inorganic Mass Spectrometry

Ion Chromatography

Molecular Spectroscopy and Microanalysis

Columns and Consumables

Life Sciences Mass Spectrometry

Services and Training

Contact for more information: 102, 104, Delphi‚ ‘C‘ Wing, Hiranandani Business Park, Powai, Mumbai - 400 076. INDIA. • Tel:+91-22-6742 9494 • Email ID: analyze.in@thermofisher.com

REGD.WITH RNI NO.MAHENG/2005/21398 REGD.NO.MH/MR/SOUTH-77/2010-12, PUBLISHED ON 5TH & 20TH EVERY FORTNIGHLY & POSTED 6-7-8 & 21-22-23 OF EVERY FORTNIGHLY. AT IND.EXP.PSO. From the makers of:

Saves Time

CHOOSE THE EXPERT

`

Saves Cost

Ready to use Expert System For Extended Release Instamodel has been developed to fulfill requirements of quick ER formulations launch.

The processes is simple involving blending, granulation (dry or wet) and conventional tablet manufacturing.

Complete compliance to pharmacopeial dissolution requirements.

Appearance and in vitro drug release profile comparable to the brand leader and innovator products.

Presently available for â&#x20AC;&#x201C; Diclofenac ER tablets 100 mg, Metformin HCl ER Tablets 500 & 1000 mg, Metoprolol succinate ER Tablets 25, 50, 100 and 200 mg, Acetaminophen ER Tablets 650 mg, Carbamazepine 200 mg, Trimetazidine Hydrochloride 35 mg, Aceclofenac 200 mg, many more in the pipeline.

C . omplete technical support available for manufacturing of initial batch

Open QR reader application on your smartphone and scan

A 223-229, Virwani Industrial Estate, Western Express Highway, Goregaon (East), Mumbai - 400 063 , India Tel: +91-22-42688700 Fax: +91-22-42688713 E-mail: info@idealcures.co.in Website: www.idealcures.co.in